| P/E (FY) | 67.9 | Sales (TTM) | $541.7M |
| Earnings (TTM) | $88.0M | ROE | 5.34% |
| Net Margin | 12.83% | ROIC | 5.97% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 20.37% |
Veracyte is a diagnostics company operating in the United States and internationally. It offers the Afirma Genomic Sequencing Classifier for thyroid nodules, Decipher classifiers for prostate and bladder cancer, the Prosigna Breast Cancer Assay, and the Percepta Nasal Swab Test for lung cancer. It also provides nCounter analysis system services and is headquartered in South San Francisco, California.
| Market Cap | $4.44B | Trading Days | 3201 |
| 52W High | 60.91 |
| 52W Low | 22.92 |
| % Off High | −8.64% |
| YTD | 32.19% | 1Y | 122.42% |
| 3Y | 98.04% | 5Y | 41.06% |
| 10Y | 1021.98% | Since incept. (ann.) | 11.92% |
Reportable 100%
| Ann. Volatility (1Y) | 60.77% | Ann. Volatility (3Y) | 55.02% |
| Sharpe (1Y) | 1.62 | Sharpe (3Y) | 0.70 |
| Max Drawdown (1Y) | −39.23% | Max Drawdown (3Y) | −50.09% |
| Beta (3Y, vs SPY) | 1.84 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CAI | Caris Life Sciences, Inc. | $4.41B | — |
| CELC | Celcuity Inc. | $4.02B | — |
| RDNT | RadNet, Inc. | $4.97B | — |
| BLLN | BillionToOne, Inc. | $2.84B | 380.6 |
| GRAL | GRAIL, Inc. | $2.76B | — |
| FTRE | Fortrea Holdings Inc. | $1.96B | — |
| CDNA | CareDx, Inc. | $1.85B | — |
| PSNL | Personalis, Inc. | $1.24B | — |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.05B | — |
| GH | Guardant Health, Inc. | $19.04B | — |
| LH | LABCORP HOLDINGS INC. | $25.77B | 30.0 |
| DGX |
| $26.04B |
| 27.0 |
